Intranasal esketamine effective for geriatric patients with treatment-resistant depression
Almost twice as many geriatric patients with treatment-resistant depression showed a 50 percent response when treated with intranasal esketamine in combination with oral antidepressants compared with those treated with intranasal placebo and oral antidepressants, according to data presented at the 2018 American Psychiatric Association Annual Meeting. Results also show that intranasal esketamine in combination with oral antidepressants demonstrated significant reduction of depressive symptoms and improved overall severity of depressive illness and health-related quality of life and functioning at 4 weeks.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063